Atossa Therapeutics CEO Dr. Steven Quay Emphasizes Importance of Breast Cancer Screening During Breast Cancer Awareness Month
Global Pandemic Caused a Significant Drop In Mammograms as Clinics Remained Closed
SEATTLE, Oct. 21, 2021 (GLOBE NEWSWIRE) — Dr. Steven Quay, CEO of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today released a short video message recognizing Breast Cancer Awareness Month, and urging women to get mammograms.
In the video message, which can be found on Atossa’s website here, Dr. Quay cites that the global pandemic “changed everything” with regard to breast cancer screening, indicating that many women have ceased to seek out their mammograms since the initial COVID-19 outbreak. This is corroborated in an article in the October 2021 issue of the peer-reviewed medical journal, Preventative Medicine, which indicated this was a particular problem in women of color and those who fall in the lower income brackets.
ABOUT ATOSSA THERAPEUTICS
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19. For more information, please visit www.atossatherapeutics.com.
FORWARD-LOOKING STATEMENTS DISCLAIMER STATEMENT
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering, the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence and continue studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study or reduction of breast density will be approvable endpoints for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
COMPANY CONTACT:
Atossa Therapeutics, Inc.
Kyle Guse, CFO and General Counsel
Office: (866) 893-4927
kyle.guse@atossainc.com
INVESTOR RELATIONS CONTACT:
Core IR
Office: (516) 222-2560
ir@atossainc.com
